Primary Peritoneal Serous Adenocarcinoma Completed Phase 2 Trials for Cediranib (DB04849)

IndicationStatusPhase
DBCOND0030567 (Primary Peritoneal Serous Adenocarcinoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00275028AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube CancerTreatment